All Releases
 |
Momenta Pharmaceuticals to Present at The Cowen and Company 30th Annual Healthcare Conference
Mar 3, 2010
|
7.0 KB |
|
| |
CAMBRIDGE, Mass., Mar 3, 2010 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, Chief Executive Officer, will deliver a corporate presentation at The Cowen and Company 30th Annual H...
|
|
Momenta Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year End 2009
Feb 11, 2010
|
14.6 KB |
|
| |
CAMBRIDGE, Mass., Feb 11, 2010 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the fourth quarter and year ended December 31, 2009.
For the fourth quarter of 2009 the Com...
|
|
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Fourth Quarter and Year Ended 2009 Financial Results
Feb 4, 2010
|
7.5 KB |
|
| |
CAMBRIDGE, Mass., Feb 4, 2010 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will report its financial results for the fourth quarter and year ended December 31, 2009 before the U.S. financial markets open on Thurs...
|
|
Momenta Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Jan 29, 2010
|
7.0 KB |
|
| |
CAMBRIDGE, Mass., Jan 29, 2010 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, Chief Executive Officer, will deliver a corporate presentation at The 12th Annual BIO CEO & Investor...
|
|
Momenta Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
Nov 12, 2009
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Nov 12, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard P. Shea, Chief Financial Officer, will deliver a corporate presentation at the Lazard Capital Markets 6th A...
|
|
Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
Nov 5, 2009
|
19.9 KB |
|
| |
CAMBRIDGE, Mass., Nov 5, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the third quarter ended September 30, 2009.
For the third quarter of 2009, the Company repor...
|
|
Momenta Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
Oct 30, 2009
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Oct 30, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard P. Shea, Chief Financial Officer, will deliver a corporate presentation at the Oppenheimer 20th Annual Heal...
|
|
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2009 Financial Results
Oct 29, 2009
|
14.6 KB |
|
| |
CAMBRIDGE, Mass., Oct 29, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will report its financial results for the third quarter ended September 30, 2009 before the U.S. financial markets open on Thursday, Nov...
|
|
Momenta Pharmaceuticals, Inc. Announces Closing of Offering and Exercise of Over-Allotment Option
Sep 28, 2009
|
14.0 KB |
|
| |
CAMBRIDGE, Mass., Sep 28, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the closing of its underwritten public offering of 4,600,000 shares of its common stock, which includes the full exercis...
|
|
Momenta Pharmaceuticals Announces Positive Results From M118 EMINENCE Trial
Sep 24, 2009
|
21.9 KB |
|
| |
CAMBRIDGE, Mass., Sep 24, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) Phase 2 multicenter trial evalu...
|
|
Momenta Pharmaceuticals Prices Underwritten Offering of Common Stock
Sep 23, 2009
|
14.4 KB |
|
| |
CAMBRIDGE, Mass., Sep 23, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price of $10.75 per share. After un...
|
|
Momenta Pharmaceuticals to Present At the 2009 UBS Global Life Sciences Conference
Sep 21, 2009
|
14.1 KB |
|
| |
CAMBRIDGE, Mass., Sep 21, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard P. Shea, Chief Financial Officer, will deliver a corporate presentation at the 2009 UBS Global Life Science...
|
|
Momenta Pharmaceuticals Announces EMINENCE Trial Results to be Presented At the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) Meeting
Sep 9, 2009
|
14.5 KB |
|
| |
CAMBRIDGE, Mass., Sep 9, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that clinical trial results from the Phase 2 EMINENCE trial of its rationally engineered anticoagulant, M118, wil...
|
|
Momenta Pharmaceuticals to Present At the Rodman & Renshaw 11th Annual Global Investment Conference
Sep 2, 2009
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Sep 2, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, President and Chief Executive Officer, will deliver a corporate presentation at the Rodman & Renshaw ...
|
|
Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2009
Aug 6, 2009
|
21.8 KB |
|
| |
CAMBRIDGE, Mass., Aug 6, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today reported its financial results for the quarter ended June 30, 2009.
For the second quarter of 2009, the Company reported a net ...
|
|
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2009 Financial Results
Jul 23, 2009
|
14.6 KB |
|
| |
CAMBRIDGE, Mass., Jul 23, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will report its financial results for the second quarter ended June 30, 2009 before the U.S. financial markets open on Thursday, August ...
|
|
Momenta Pharmaceuticals Announces Top-Line Results From the M118 EMINENCE Trial
Jun 29, 2009
|
18.8 KB |
|
| |
CAMBRIDGE, Mass., Jun 29, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) phase 2 multicenter study ...
|
|
Momenta Pharmaceuticals Announces Appointment of Bruce L. Downey to Board of Directors
Jun 12, 2009
|
16.2 KB |
|
| |
CAMBRIDGE, Mass., Jun 12, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced the appointment of Bruce L. Downey to its Board of Directors, effective June 11, 2009. Mr. Downey is the former Chairman and C...
|
|
Momenta Pharmaceuticals to Present At the Goldman Sachs 30th Annual Global Healthcare Conference
Jun 3, 2009
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., Jun 3, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Craig Wheeler, President and Chief Executive Officer, will deliver a corporate presentation at the Goldman Sachs 30t...
|
|
Momenta Pharmaceuticals to Present At the Deutsche Bank 34th Annual Health Care Conference
May 12, 2009
|
14.2 KB |
|
| |
CAMBRIDGE, Mass., May 12, 2009 (GlobeNewswire via COMTEX News Network) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that Richard Shea, Chief Financial Officer, will deliver a corporate presentation at the Deutsche Bank 34th Annual Healt...
|
|
|
